Formulation and Development of Bilayer Tablet for Irritable Bowel Disease

The objective of the present research was to formulate and develop a bilayer tablet containing Metronidazole and Dicyclomine Hydrochloride for the effective treatment of Irritable Bowel Disease. Metronidazole was incorporated as an immediate‑release layer, whereas Dicyclomine Hydrochloride was formulated as a sustained‑release layer. The rationale behind combining these two drugs in a bilayer system lies in their therapeutic roles: Metronidazole (immediate release) acts as a potent antibiotic commonly used in antidiarrheal therapy for the treatment of inflammation in the large intestine, while Dicyclomine Hydrochloride (sustained release) is an anticholinergic agent primarily administered for irritable bowel disease. The bilayer design enhances therapeutic efficacy by enabling sequential and controlled drug release profiles suitable for managing irritable bowel disease.